Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

Apoptosis by Death Factor

Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,908 · see citing works

Bone marrow transplant

Joyce, A. (1989) · Nursing Children and Young People · doi:10.7748/paed.1.6.21.s21 · Cited by 3,410 · see citing works

Identification and characterization of a new member of the TNF family that induces apoptosis

Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900 · see citing works

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 1,990 · see citing works

The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death

Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,909 · see citing works

Tumor Necrosis Factor (TNF)

Old, L. J. (1985) · Science · doi:10.1126/science.2413547 · Cited by 1,885 · see citing works

Lethal effect of the anti-Fas antibody in mice

Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881 · see citing works

Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)

Dhein, J., Walczak, H., Bäumler, C., Debatin, K., & Krammer, P. (1995) · Nature · doi:10.1038/373438a0 · Cited by 1,814 · see citing works

Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family

Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,777 · see citing works

Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice

Kägi, D., Ledermann, B., Bürki, K., Seiler, P. J., Odermatt, B., Olsen, K. J., Podack, E. R., Zinkernagel, R. M., & Hengartner, H. (1994) · Nature · doi:10.1038/369031a0 · Cited by 1,758 · see citing works

The Receptor for the Cytotoxic Ligand TRAIL

Pan, G., O’Rourke, K. M., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,755 · see citing works

Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation

Ju, S., Panka, D., Cui, H., Ettinger, R., EI-Khatib, M., Sherr, D., Stanger, B., & Marshak-Rothstein, A. (1995) · Nature · doi:10.1038/373444a0 · Cited by 1,709 · see citing works

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682 · see citing works

Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors

Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A. L., Skubatch, M., Baldwin, D. T., Ramakrishnan, L., Gray, C. L., Baker, K. P., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664 · see citing works

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R., Weaver, A. L., Ettlinger, R. E., Cohen, S. B., Koopman, W. J., Mohler, K. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,620 · see citing works

An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL

Pan, G., Ni, J., Wei, Y.-F., Yu, G.-L., Gentz, R., & Dixit, V. M. (1997) · Science · doi:10.1126/science.277.5327.815 · Cited by 1,486 · see citing works

Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome

Fisher, G. H., Rosenberg, F. J., Straus, S. E., Dale, J. K., Middelton, L. A., Lin, A. Y., Strober, W., Lenardo, M. J., & Puck, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90013-6 · Cited by 1,454 · see citing works

Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas

Brunner, T., Mogil, R. J., LaFace, D., Yoo, N. J., Mahboubi, A., Echeverri, F., Martin, S. J., Force, W. R., Lynch, D. H., Ware, C. F., et al. (1995) · Nature · doi:10.1038/373441a0 · Cited by 1,314 · see citing works

Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

Hahne, M., Rimoldi, D., Schröter, M., Romero, P. J., Schreier, M. H., French, L. E., Schneider, P., Bornand, T., Fontana, A., Liénard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,236 · see citing works

Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL

Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S. D., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,183 · see citing works

A role for CD95 ligand in preventing graft rejection

Bellgrau, D., Gold, D. P., Selawry, H. P., Moore, J. K., Franzusoff, A., & Duke, R. C. (1995) · Nature · doi:10.1038/377630a0 · Cited by 1,147 · see citing works

TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL

Walczak, H., Degli‐Esposti, M. A., Johnson, R. S., Smolak, P. J., Waugh, J. Y., Boiani, N., Timour, M. S., Gerhart, M. J., Schooley, K. A., Smith, C. A., et al. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5386 · Cited by 1,130 · see citing works

Induction of apoptosis in mature T cells by tumour necrosis factor

Zheng, L., Fisher, G. H., Miller, R. E., Peschon, J. J., Lynch, D. H., & Lenardo, M. J. (1995) · Nature · doi:10.1038/377348a0 · Cited by 1,116 · see citing works

Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways

Lowin, B., Hahne, M., Mattmann, C., & Tschopp, J. (1994) · Nature · doi:10.1038/370650a0 · Cited by 1,052 · see citing works

Fas ligand mediates activation-induced cell death in human T lymphocytes.

Alderson, M. R., Tough, T. W., Davis-Smyth, T., Braddy, S., Falk, B. A., Schooley, K., Goodwin, R. G., Smith, C. A., Ramsdell, F., & Lynch, D. H. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.1.71 · Cited by 933 · see citing works

Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?

Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, G., Strand, D. J., Mariani, S. M., Stremmel, W., Krammer, P. H., & Galle, P. R. (1996) · Nature Medicine · doi:10.1038/nm1296-1361 · Cited by 897 · see citing works

The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain

Degli‐Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., & Goodwin, R. G. (1997) · Immunity · doi:10.1016/s1074-7613(00)80399-4 · Cited by 815 · see citing works

Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity

Schneider, P., Holler, N., Bodmer, J.-L., Hahne, M., Frei, K., Fontana, A., & Tschopp, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1205 · Cited by 804 · see citing works

Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

Galle, P. R., Hofmann, W. J., Walczak, H., Schaller, H., Otto, G., Stremmel, W., Krammer, P. H., & Runkel, L. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.5.1223 · Cited by 692 · see citing works

Tumor necrosis factor Characterization at the molecular, cellular and in vivo level

Fiers, W. C. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80803-b · Cited by 684 · see citing works

Intracellular Regulation of TRAIL-Induced Apoptosis in Human Melanoma Cells

Griffith, T. S., Chin, W. A., Jackson, G. C., Lynch, D. H., & Kubin, M. Z. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2833 · Cited by 663 · see citing works

A novel receptor for Apo2L/TRAIL contains a truncated death domain

Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A. J. Y., Skubatch, M., Baldwin, D. T., Yuan, J., Gurney, A. L., Goddard, A. D., Godowski, P. J., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00422-2 · Cited by 654 · see citing works

Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family

Degli‐Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J. Y., Huang, C.-P., DuBose, R. F., Goodwin, R. G., & Smith, C. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1165 · Cited by 630 · see citing works

Essential roles of the Fas ligand in the development of hepatitis

Kondo, T., Suda, T., Fukuyama, H., Adachi, M., & Nagata, S. (1997) · Nature Medicine · doi:10.1038/nm0497-409 · Cited by 470 · see citing works

Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover.

French, L. E., Hahne, M., Viard, I., Radlgruber, G., Zanone, R., Becker, K., Müller, C., & Tschopp, J. (1996) · The Journal of Cell Biology · doi:10.1083/jcb.133.2.335 · Cited by 445 · see citing works

The role of cachectin/TNF in endotoxic shock and cachexia

Ceramil, A., & Beutler, B. (1988) · Immunology Today · doi:10.1016/0167-5699(88)91353-9 · Cited by 328 · see citing works

Tumor necrosis factor receptor superfamily members and their ligands

Armitage, R. J. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90119-8 · Cited by 308 · see citing works

The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.

Havell, E. A., Fiers, W. C., & North, R. J. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.167.3.1067 · Cited by 274 · see citing works

In vivo anti‐tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN‐γ, on a syngeneic murine melanoma

Brouckaert, P., Leroux-Roels, G. G., Guisez, Y., Tavernier, J. H., & Fiers, W. (1986) · International Journal of Cancer · doi:10.1002/ijc.2910380521 · Cited by 177 · see citing works

Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells.

Vandenabeele, P., Declercq, W., Vanhaesebroeck, B., Grooten, J., & Fiers, W. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.6.2904 · Cited by 169 · see citing works

Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes

Tanaka, M., Suda, T., Yatomi, T., Nakamura, N., & Nagata, S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.5.2303 · Cited by 160 · see citing works

Structural characteristics of CD40 ligand that determine biological function

Fanslow, W. C., Srinivasan, S., Paxton, R., Gibson, M. G., Spriggs, M. K., & Armitage, R. J. (1994) · Seminars in Immunology · doi:10.1006/smim.1994.1035 · Cited by 155 · see citing works

Interleukin 1β-converting Enzyme Related Proteases/Caspases Are Involved in TRAIL-induced Apoptosis of Myeloma and Leukemia Cells

Mariani, S. M., Matiba, B., Armandola, E. A., & Krammer, P. H. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.221 · Cited by 142 · see citing works

A family of ligands for the TNF receptor superfamily

Cosman, D. J. (1994) · Stem Cells · doi:10.1002/stem.5530120501 · Cited by 125 · see citing works

The CD95 system and the death of a lymphocyte

Matiba, B., Mariani, S. M., & Krammer, P. H. (1997) · Seminars in Immunology · doi:10.1006/smim.1996.0054 · Cited by 68 · see citing works

Cytokines as mediators of graft-versus-host disease.

Cohen, J. (1988) · PubMed · Cited by 34 · see citing works

AIDS and the death receptors

Peter, M. E., Ehret, A., Berndt, C., & Krammer, P. (1997) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a011633 · Cited by 19 · see citing works

Interferons: Cytokines in Autoimmunity

Revel, M., & Schattner, A. (2007) · Novartis Foundation symposium · doi:10.1002/9780470513484.ch15 · Cited by 9 · see citing works

The TNF and TNF Receptor Superfamilies

Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650 · see citing works

Safety and antitumor activity of recombinant soluble Apo2 ligand

Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213 · see citing works

Death and anti-death: tumour resistance to apoptosis

Igney, F. H., & Krammer, P. H. (2002) · Nature reviews. Cancer · doi:10.1038/nrc776 · Cited by 2,073 · see citing works

Cytokines in cancer pathogenesis and cancer therapy

Dranoff, G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1252 · Cited by 1,567 · see citing works

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

Ashkenazi, A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc821 · Cited by 1,351 · see citing works

Ovarian cancer: strategies for overcoming resistance to chemotherapy

Agarwal, R., & Kaye, S. B. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1123 · Cited by 1,155 · see citing works

Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5

Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975 · see citing works

Engineering the perfect (bacterial) cancer therapy

Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905 · see citing works

TRAIL and apoptosis induction by TNF-family death receptors

Wang, S., & El‐Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1207232 · Cited by 869 · see citing works

Apo2L/TRAIL and its death and decoy receptors

LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 856 · see citing works

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

Jo, M., Kim, T., Seol, D., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843 · see citing works

The TRAIL apoptotic pathway in cancer onset, progression and therapy

Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2465 · Cited by 835 · see citing works

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works

FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2

Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H., & Walczak, H. (2000) · Immunity · doi:10.1016/s1074-7613(00)80211-3 · Cited by 799 · see citing works

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells

Takeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita∥, H., & Okumura, K. (2001) · Nature Medicine · doi:10.1038/83416 · Cited by 771 · see citing works

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

Fulda, S., Wick, W., Weller, M., & Debatin, K. (2002) · Nature Medicine · doi:10.1038/nm735 · Cited by 736 · see citing works

Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors

Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.09.011 · Cited by 723 · see citing works

Lysosomes in cell death

Guicciardi, M. E., Leist, M., & Gores, G. J. (2004) · Oncogene · doi:10.1038/sj.onc.1207512 · Cited by 716 · see citing works

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

Lawrence, D. A., Shahrokh, Z., Marsters, S. A., Achilles, K., Shih, D., Mounho, B. J., Hillan, K. J., Tótpál, K., DeForge, L. E., Schow, P. W., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702 · see citing works

Apoptosis: a basic biological phenomenon with wide‐ranging implications in human disease

Fadeel, B., & Orrenius, S. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01570.x · Cited by 699 · see citing works

Apoptosis and Necrosis in the Liver: A Tale of Two Deaths?

Malhi, H., Gores, G. J., & Lemasters, J. J. (2006) · Hepatology · doi:10.1002/hep.21062 · Cited by 688 · see citing works

Life and death by death receptors

Guicciardi, M. E., & Gores, G. J. (2009) · The FASEB Journal · doi:10.1096/fj.08-111005 · Cited by 689 · see citing works

From bench to clinic with apoptosis-based therapeutic agents

Nicholson, D. W. (2000) · Nature · doi:10.1038/35037747 · Cited by 685 · see citing works

Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II

Wang, J., Zheng, L., Lobito, A. A., Chan, F. K.-M., Dale, J. K., Sneller, M. C., Xu, Y., Puck, J. M., Straus, S. E., & Lenardo, M. J. (1999) · Cell · doi:10.1016/s0092-8674(00)80605-4 · Cited by 639 · see citing works

The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems

Walczak, H., & Krammer, P. H. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4840 · Cited by 624 · see citing works

Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice

Cretney, E., Takeda, K., Yagita∥, H., Glaccum, M. B., Peschon, J. J., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1356 · Cited by 615 · see citing works

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Álvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2004) · Nature Medicine · doi:10.1038/nm1161 · Cited by 613 · see citing works

Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression

Luo, J., Maeda, S., Hsu, L.-C., Yagita∥, H., & Karin, M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.012 · Cited by 598 · see citing works

Cellular FLICE-inhibitory Protein Splice Variants Inhibit Different Steps of Caspase-8 Activation at the CD95 Death-inducing Signaling Complex

Krueger, A., Schmitz, I., Baumann, S., Krammer, P. H., & Kirchhoff, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101780200 · Cited by 565 · see citing works

Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy

von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556 · see citing works

Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy

Almasan, A., & Ashkenazi, A. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00029-7 · Cited by 547 · see citing works

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity

Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 544 · see citing works

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

Chinnaiyan, A. M., Prasad, U., Shankar, S., Hamstra, D. A., Shanaiah, M., Chenevert, T. L., Ross, B. D., & Rehemtulla, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.030545097 · Cited by 528 · see citing works

Chemotherapeutic Approaches for Targeting Cell Death Pathways

Ricci, M., & Zong, W. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-342 · Cited by 512 · see citing works

Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis

Smyth, M. J., Cretney, E., Takeda, K., Wiltrout, R. H., Sedger, L. M., Kayagaki, N., Yagita∥, H., & Okumura, K. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.661 · Cited by 512 · see citing works

Anticancer therapy targeting the apoptotic pathway

Hu, W., & Kavanagh, J. J. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01277-4 · Cited by 511 · see citing works

Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax

LeBlanc, H. N., Lawrence, D. A., Varfolomeev, E. E., Tótpál, K., Morlan, J., Schow, P. W., Fong, S. E., SCHWALL, R. H., Sinicropi, D. V., & Ashkenazi, A. (2002) · Nature Medicine · doi:10.1038/nm0302-274 · Cited by 500 · see citing works

Death receptors in chemotherapy and cancer

Debatin, K., & Krammer, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207558 · Cited by 505 · see citing works

The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond

Dostert, C., Grusdat, M., Letellier, E., & Brenner, D. (2018) · Physiological Reviews · doi:10.1152/physrev.00045.2017 · Cited by 502 · see citing works

Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL

Griffith, T. S., Wiley, S. R., Kubin, M. Z., Sedger, L. M., Maliszewski, C. R., & Fanger, N. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1343 · Cited by 477 · see citing works

Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development

Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita∥, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 462 · see citing works

Getting TRAIL back on track for cancer therapy

Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.81 · Cited by 455 · see citing works

TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLOPreprint

Deng, Y., Lin, Y., & Wu, X. (2002) · Genes & Development · doi:10.1101/gad.949602 · Cited by 456 · see citing works

A fate worse than death: apoptosis as an oncogenic process

Ichim, G., & Tait, S. W. G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.58 · Cited by 451 · see citing works

Preclinical Studies to Predict the Disposition of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Humans: Characterization of in Vivo Efficacy, Pharmacokinetics, and Safety

Kelley, S. K., Harris, L. A., Xie, D., DeForge, L. E., Tótpál, K., Bussiere, J., & Fox, J. A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29298-3 · Cited by 439 · see citing works

Natural Killer Cells and Cancer

Wu, J., & Lanier, L. L. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)90004-2 · Cited by 435 · see citing works

Triggering Cell Death

Hymowitz, S. G., Christinger, H. W., Fuh, G., Ultsch, M. H., O'Connell, M., Kelley, R. F., Ashkenazi, A., & de Vos, A. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80207-5 · Cited by 434 · see citing works

Directing cancer cells to self-destruct with pro-apoptotic receptor agonists

Ashkenazi, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2637 · Cited by 431 · see citing works

Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage

Dunn, C., Brunetto, M. R., Reynolds, G. M., Christophides, T., Kennedy, P. T. F., Lampertico, P., Das, A., Lopes, A. R., Borrow, P., Williams, K. T., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061287 · Cited by 421 · see citing works

Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways

Suliman, A., Lam, A., Datta, R., & Srivastava, R. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204282 · Cited by 417 · see citing works

Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer

Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417 · see citing works

Human Dendritic Cells Mediate Cellular Apoptosis via Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail)

Fanger, N. A., Maliszewski, C. R., Schooley, K., & Griffith, T. S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.8.1155 · Cited by 415 · see citing works

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64556-7 · Cited by 391 · see citing works

Targeting apoptotic caspases in cancer

Boice, A., & Bouchier‐Hayes, L. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118688 · Cited by 402 · see citing works

Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression

Fulda, S., Meyer, É., & Debatin, K. (2002) · Oncogene · doi:10.1038/sj.onc.1205258 · Cited by 394 · see citing works

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

Mitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P. G. G., Schlossman, R. L., Hideshima, T., & Anderson, K. C. (2001) · Blood · doi:10.1182/blood.v98.3.795 · Cited by 391 · see citing works

Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.

Nagane, M., Pan, G., Weddle, J. J., Dixit, V. M., Cavenee, W. K., & Huang, H. (2000) · PubMed · Cited by 387 · see citing works

Molecular determinants of response to TRAIL in killing of normal and cancer cells.

Kim, K., Fisher, M. J., Xu, S., & El‐Deiry, W. S. (2000) · PubMed · Cited by 376 · see citing works

Modes of Regulated Cell Death in Cancer

Koren, E., & Fuchs, Y. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0789 · Cited by 378 · see citing works

Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

Cuello, M. A., Ettenberg, S. A., Clark, A. S., Keane, M., Posner, R. H., Nau, M. M., Dennis, P. A., & Lipkowitz, S. (2001) · PubMed · Cited by 370 · see citing works

Targeting death receptors in cancer with Apo2L/TRAIL

Kelley, S. K. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.02.006 · Cited by 370 · see citing works

Nature's TRAIL—On a Path to Cancer Immunotherapy

Smyth, M. J., Takeda, K., Hayakawa, Y., Peschon, J. J., van den Brink, M. R. M., & Yagita∥, H. (2003) · Immunity · doi:10.1016/s1074-7613(02)00502-2 · Cited by 360 · see citing works

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.

Condamine, T., Kumar, V., Ramachandran, I. R., Youn, J.-I., Celis, E., Finnberg, N., El-Deiry, W. S., Winograd, R., Vonderheide, R. H., English, N. R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74056 · Cited by 365 · see citing works

Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression

Song, K., Chen, Y., Göke, R., Wilmen, A., Seidel, C., Göke, A., Hilliard, B. A., & Chen, Y. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.7.1095 · Cited by 361 · see citing works

Apoptosis and Necrosis in the Liver

Guicciardi, M. E., Malhi, H., Mott, J. L., & Gores, G. J. (2013) · Comprehensive physiology · doi:10.1002/cphy.c120020 · Cited by 387 · see citing works

Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects

Allen, J. E., Krigsfeld, G. S., Mayes, P. A., Patel, L., Dicker, D. T., Patel, A. S., Dolloff, N. G., Messaris, E. G., Scata, K. A., Wang, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004828 · Cited by 341 · see citing works

Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice

Lamhamedi-Cherradi, S.-E., Zheng, S. J., Maguschak, K. A., Peschon, J. J., & Chen, Y. H. (2003) · Nature Immunology · doi:10.1038/ni894 · Cited by 347 · see citing works

Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential

Shankar, S. (2007) · Frontiers in bioscience · doi:10.2741/2432 · Cited by 340 · see citing works

Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL

Altucci, L., Rossin, A., Raffelsberger, W., Reitmair, A., Chomienne, C., & Gronemeyer, H. (2001) · Nature Medicine · doi:10.1038/89050 · Cited by 340 · see citing works

Expression and Function of TNF-Related Apoptosis-Inducing Ligand on Murine Activated NK Cells

Kayagaki, N., Yamaguchi, N., Nakayama, M., Takeda, K., Akiba, H., Tsutsui, H., Okamura, H., Nakanishi, K., Okumura, K., & Yagita∥, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.1906 · Cited by 338 · see citing works

Protein Complexes Activate Distinct Caspase Cascades in Death Receptor and Stress-Induced Apoptosis

Bratton, S. B., MacFarlane, M., Cain, K., & Cohen, G. M. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4835 · Cited by 334 · see citing works

MAPK/ERK Overrides the Apoptotic Signaling from Fas, TNF, and TRAIL Receptors

Tran, S. E. F., Holmström, T. H., Ahonen, M., Kähäri, V., & Eriksson, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010384200 · Cited by 329 · see citing works

The TRAIL to selective tumor death

French, L. E., & Tschopp, J. (1999) · Nature Medicine · doi:10.1038/5505 · Cited by 321 · see citing works

To kill a tumor cell: the potential of proapoptotic receptor agonists

Ashkenazi, A., & Herbst, R. S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34359 · Cited by 320 · see citing works

The crosstalk between autophagy and apoptosis: where does this lead?

Gordy, C. L., & He, Y.-W. (2012) · Protein & Cell · doi:10.1007/s13238-011-1127-x · Cited by 322 · see citing works

Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB

Ravi, R. K., Bedi, G. C., Engstrom, L., Zeng, Q., Mookerjee, B., Gélinas, C., Fuchs, E. J., & Bedi, A. (2001) · Nature Cell Biology · doi:10.1038/35070096 · Cited by 313 · see citing works

Insights into programmed cell death through structural biology.

Fesik, S. (2000) · Cell · doi:10.1016/s0092-8674(00)00119-7 · Cited by 328 · see citing works

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306 · see citing works

Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2

Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, É., & Micheau, O. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00520-06 · Cited by 306 · see citing works

TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways

Secchiero, P., Gonelli, A., Carnevale, E., Milani, D., Pandolfi, A., Zella, D., & Zauli, G. (2003) · Circulation · doi:10.1161/01.cir.0000062702.60708.c4 · Cited by 303 · see citing works

Onto better TRAILs for cancer treatment

de Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martínez‐Lostao, L. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2015.174 · Cited by 304 · see citing works

Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics

Krakstad, C., & Chekenya, M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-135 · Cited by 301 · see citing works

Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

Nitsch, R., Bechmann, I., Deisz, R. A., Haas, D., Lehmann, T.-N., Wendling, U., & Zipp, F. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02659-3 · Cited by 301 · see citing works

Following TRAIL’s path in the immune system

Falschlehner, C., Schaefer, U., & Walczak, H. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03058.x · Cited by 300 · see citing works

Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system

Eißner, G., Kölch, W., & Scheurich, P. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.011 · Cited by 298 · see citing works

Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer

Chen, X., Thakkar, H., Tyan, F., Gim, S., Robinson, H. M., Lee, C., Pandey, S., Nwokorie, C., Onwudiwe, N. C., & Srivastava, R. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204736 · Cited by 298 · see citing works

Cytokines, Inflammation and Colon Cancer

Klampfer, L. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911795538066 · Cited by 290 · see citing works

MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer

Garofalo, M., Quintavalle, C., Leva, G. D., Zanca, C., Romano, G., Taccioli, C., Liu, C. G., Croce, C. M., & Condorelli, G. (2008) · Oncogene · doi:10.1038/onc.2008.6 · Cited by 290 · see citing works

Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.

Leverkus, M., Neumann, M., Mengling, T., Rauch, C. T., Bröcker, E. B., Krammer, P. H., & Walczak, H. (2000) · PubMed · Cited by 288 · see citing works

Cell surface Death Receptor signaling in normal and cancer cells

Özören, N., & El‐Deiry, W. S. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00131-1 · Cited by 289 · see citing works

Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling

Kelley, R. F., Tótpál, K., Lindstrom, S. H., Mathieu, M. A., Billeci, K. L., DeForge, L. E., Pai, R., Hymowitz, S. G., & Ashkenazi, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410660200 · Cited by 279 · see citing works

Structural principles of tumor necrosis factor superfamily signaling

Vanamee, É. S., & Faustman, D. L. (2018) · Science Signaling · doi:10.1126/scisignal.aao4910 · Cited by 284 · see citing works

Apoptosis-based therapies and drug targets

Fischer, U., & Schulze‐Osthoff, K. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401556 · Cited by 280 · see citing works

TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer

Srivastava, R. K. (2001) · Neoplasia · doi:10.1038/sj.neo.7900203 · Cited by 279 · see citing works

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

Dimberg, L. Y., Anderson, C. K., Camidge, D. R., Behbakht, K., Thorburn, A. M., & Ford, H. L. (2012) · Oncogene · doi:10.1038/onc.2012.164 · Cited by 276 · see citing works

TRAIL on trial: preclinical advances in cancer therapy

Stuckey, D. W., & Shah, K. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.08.007 · Cited by 274 · see citing works

Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis

Hinz, S., Trauzold, A., Boenicke, L., Sandberg, C., Beckmann, S., Bayer, E., Walczak, H., Kalthoff, H., & Ungefroren, H. (2000) · Oncogene · doi:10.1038/sj.onc.1203936 · Cited by 275 · see citing works

Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape

DeSelm, C. J., Palomba, M. L., Yahalom, J., Hamieh, M., Eyquem, J., Rajasekhar, V. K., & Sadelain, M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.008 · Cited by 275 · see citing works

TRAIL receptor signalling and modulation: Are we on the right TRAIL?

Mahalingam, D., Szegezdi, É., Keane, M., de Jong, S., & Samali, A. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.006 · Cited by 271 · see citing works

TRAIL Inhibits Tumor Growth but Is Nontoxic to Human Hepatocytes in Chimeric Mice

Hao, C., Song, J. H., Hsi, B., Lewis, J. T., Song, D. K., Petruk, K. C., Tyrrell, D., & Kneteman, N. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2599 · Cited by 147 · see citing works

The investigation of the relationship between tumor necrosis factor-related apoptosis-inducing ligand and tumor therapy

Liang, Z. (2008) · Fudan xuebao. Yixue ban

Apoptosis Induction by TRAIL

Eggert, A., Sieverts, H., & Walczak, H. (2003) · Humana Press eBooks · doi:10.1385/1-59259-345-3:95 · Cited by 1 · see citing works

The TRAIL to an anti-cancer agent

El‐Deiry, W. S. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0075 · Cited by 6 · see citing works

The TRAIL to selective tumor death

French, L. E., & Tschopp, J. (1999) · Nature Medicine · doi:10.1038/5505 · Cited by 321 · see citing works